Analysts Expect Avrobio Inc (NASDAQ:AVRO) to Announce -$0.76 EPS

Share on StockTwits

Equities research analysts expect Avrobio Inc (NASDAQ:AVRO) to report earnings of ($0.76) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Avrobio’s earnings, with estimates ranging from ($0.78) to ($0.70). Avrobio posted earnings of ($2.98) per share during the same quarter last year, which indicates a positive year over year growth rate of 74.5%. The firm is expected to report its next earnings report on Thursday, August 8th.

On average, analysts expect that Avrobio will report full year earnings of ($2.93) per share for the current year, with EPS estimates ranging from ($3.12) to ($2.54). For the next year, analysts expect that the company will post earnings of ($3.07) per share, with EPS estimates ranging from ($3.45) to ($2.65). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Avrobio.

Avrobio (NASDAQ:AVRO) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.01).

Several equities research analysts have issued reports on the stock. Mizuho assumed coverage on shares of Avrobio in a research note on Wednesday, June 26th. They issued a “buy” rating and a $28.00 price target on the stock. Cowen reiterated a “buy” rating on shares of Avrobio in a research note on Monday, July 15th. HC Wainwright set a $25.00 price objective on shares of Onconova Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, May 14th. Zacks Investment Research upgraded shares of Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Tuesday. Finally, Janney Montgomery Scott initiated coverage on shares of Amicus Therapeutics in a research note on Friday, April 5th. They set a “buy” rating and a $13.91 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $27.90.

Institutional investors have recently added to or reduced their stakes in the company. New York State Common Retirement Fund acquired a new stake in Avrobio during the 4th quarter worth approximately $113,000. BlackRock Inc. lifted its position in Avrobio by 73.4% during the 4th quarter. BlackRock Inc. now owns 651,959 shares of the company’s stock worth $10,854,000 after acquiring an additional 276,018 shares during the period. Bank of New York Mellon Corp lifted its position in Avrobio by 60.6% during the 4th quarter. Bank of New York Mellon Corp now owns 25,937 shares of the company’s stock worth $431,000 after acquiring an additional 9,782 shares during the period. Citigroup Inc. lifted its position in Avrobio by 264.8% during the 4th quarter. Citigroup Inc. now owns 13,107 shares of the company’s stock worth $218,000 after acquiring an additional 9,514 shares during the period. Finally, Northern Trust Corp lifted its position in Avrobio by 2.8% during the 4th quarter. Northern Trust Corp now owns 79,211 shares of the company’s stock worth $1,319,000 after acquiring an additional 2,170 shares during the period. Institutional investors own 71.13% of the company’s stock.

AVRO stock traded down $1.45 during midday trading on Friday, hitting $21.99. The company’s stock had a trading volume of 821,445 shares, compared to its average volume of 534,508. Avrobio has a twelve month low of $11.85 and a twelve month high of $53.70. The business has a fifty day moving average price of $15.32. The firm has a market cap of $566.01 million and a PE ratio of -6.07.

Avrobio Company Profile

AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.

Recommended Story: Initial Public Offering (IPO)

Get a free copy of the Zacks research report on Avrobio (AVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Avrobio (NASDAQ:AVRO)

Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.